Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | DNMT3A |
| Variant | R882S |
| Impact List | missense |
| Protein Effect | loss of function |
| Gene Variant Descriptions | DNMT3A R882S lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R882S results in a loss of Dnmt3a protein function, as demonstrated by cytokine-independent growth and hypomethylation in cultured cells (PMID: 31164355). |
| Associated Drug Resistance | |
| Category Variants Paths |
DNMT3A mutant DNMT3A inact mut DNMT3A R882S |
| Transcript | NM_022552.5 |
| gDNA | chr2:g.25234374G>T |
| cDNA | c.2644C>A |
| Protein | p.R882S |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_175629.2 | chr2:g.25234374G>T | c.2644C>A | p.R882S | RefSeq | GRCh38/hg38 |
| NM_022552 | chr2:g.25234374G>T | c.2644C>A | p.R882S | RefSeq | GRCh38/hg38 |
| NM_175629.2 | chr2:g.25234374G>T | c.2644C>A | p.R882S | RefSeq | GRCh38/hg38 |
| NM_175629 | chr2:g.25234374G>T | c.2644C>A | p.R882S | RefSeq | GRCh38/hg38 |
| XM_017003526.1 | chr2:g.25234374G>T | c.2644C>A | p.R882S | RefSeq | GRCh38/hg38 |
| XM_005264175 | chr2:g.25234374G>T | c.2644C>A | p.R882S | RefSeq | GRCh38/hg38 |
| XM_005264175.6 | chr2:g.25234374G>T | c.2644C>A | p.R882S | RefSeq | GRCh38/hg38 |
| XM_017003526.2 | chr2:g.25234374G>T | c.2644C>A | p.R882S | RefSeq | GRCh38/hg38 |
| NM_022552.4 | chr2:g.25234374G>T | c.2644C>A | p.R882S | RefSeq | GRCh38/hg38 |
| XM_017003526 | chr2:g.25234374G>T | c.2644C>A | p.R882S | RefSeq | GRCh38/hg38 |
| XM_005264175.5 | chr2:g.25234374G>T | c.2644C>A | p.R882S | RefSeq | GRCh38/hg38 |
| NM_022552.5 | chr2:g.25234374G>T | c.2644C>A | p.R882S | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| DNMT3A mutant | acute myeloid leukemia | resistant | Olaparib | Preclinical - Patient cell culture | Actionable | In a preclinical study, patient-derived acute myeloid leukemia cells harboring a DNMT3A mutation along with FLT3-ITD and NPM1 mutation were resistant to Lynparza (olaparib) in culture (PMID: 34215619). | 34215619 |
| DNMT3A mutant | myelofibrosis | not applicable | N/A | Guideline | Prognostic | DNMT3A mutations are associated with inferior overall survival in patients with primary myelofibrosis (NCCN.org). | detail... |
| DNMT3A mutant | acute myeloid leukemia | predicted - sensitive | Decitabine | Clinical Study - Cohort | Actionable | In a clinical study, acute myeloid leukemia patients harboring DNMT3A mutations demonstrated a greater complete response rate (60% vs 33%) compared to patients with wild-type DNMT3A when treated with frontline hypomethylating agents such as Dacogen (decitabine) (PMID: 27418649). | 27418649 |
| DNMT3A mutant | acute myeloid leukemia | not applicable | N/A | Clinical Study | Prognostic | In clinical analyses, mutations in DNMT3A were associated with poor prognosis and shorter overall survival in patients with acute myeloid leukemia (PMID: 22490330, PMID: 21881046, PMID: 21670448). | 22490330 21881046 21670448 |
| DNMT3A mutant | angioimmunoblastic T-cell lymphoma | not applicable | N/A | Guideline | Diagnostic | DNMT3A mutations aid in the diagnosis of angioimmunoblastic T-cell lymphoma (NCCN.org). | detail... |
| DNMT3A mutant | acute myeloid leukemia | sensitive | Pinometostat | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Pinometostat (EPZ-5676) treatment of acute myeloid leukemia cell lines and xenografts resulted in apoptosis, cell-cycle arrest, and terminal differentiation (PMID: 27335278). | 27335278 |